AR040090A1 - Nueva combinacion - Google Patents
Nueva combinacionInfo
- Publication number
- AR040090A1 AR040090A1 ARP030101762A ARP030101762A AR040090A1 AR 040090 A1 AR040090 A1 AR 040090A1 AR P030101762 A ARP030101762 A AR P030101762A AR P030101762 A ARP030101762 A AR P030101762A AR 040090 A1 AR040090 A1 AR 040090A1
- Authority
- AR
- Argentina
- Prior art keywords
- sildenafil citrate
- hypertension
- methyl
- inhibitor
- sildenafil
- Prior art date
Links
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 abstract 9
- 229960002639 sildenafil citrate Drugs 0.000 abstract 9
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical group CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 6
- 206010020772 Hypertension Diseases 0.000 abstract 3
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 abstract 3
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 abstract 2
- -1 3,4-Methylenedioxyphenyl Chemical group 0.000 abstract 2
- 239000005541 ACE inhibitor Substances 0.000 abstract 2
- 108010061435 Enalapril Proteins 0.000 abstract 2
- 108010007859 Lisinopril Proteins 0.000 abstract 2
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 abstract 2
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 abstract 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 2
- 229960000830 captopril Drugs 0.000 abstract 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 229960000873 enalapril Drugs 0.000 abstract 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 abstract 2
- 229960002490 fosinopril Drugs 0.000 abstract 2
- 229960002394 lisinopril Drugs 0.000 abstract 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 abstract 2
- 229960003401 ramipril Drugs 0.000 abstract 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 abstract 2
- 229960003310 sildenafil Drugs 0.000 abstract 2
- 229960002051 trandolapril Drugs 0.000 abstract 2
- INLBUQIADGPECI-UHFFFAOYSA-N 5-(5-acetyl-2-butoxypyridin-3-yl)-3-ethyl-2-(1-ethylazetidin-3-yl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCCOC1=NC=C(C(C)=O)C=C1C1=NC2=C(CC)N(C3CN(CC)C3)N=C2C(=O)N1 INLBUQIADGPECI-UHFFFAOYSA-N 0.000 abstract 1
- YPFZMBHKIVDSNR-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1=C(C=2NC(=O)C3=NN(CCOC)C(CC)=C3N=2)C(OCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 YPFZMBHKIVDSNR-UHFFFAOYSA-N 0.000 abstract 1
- FFCZQVKVWGGQFB-UHFFFAOYSA-N 9h-pyrido[3,4-b]indole-1,4-dione Chemical compound N1C2=CC=CC=C2C2=C1C(=O)N=CC2=O FFCZQVKVWGGQFB-UHFFFAOYSA-N 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 102000015427 Angiotensins Human genes 0.000 abstract 1
- 108010064733 Angiotensins Proteins 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical group C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 abstract 1
- 108010066671 Enalaprilat Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 208000007530 Essential hypertension Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 abstract 1
- 101150098694 PDE5A gene Proteins 0.000 abstract 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 abstract 1
- 201000003099 Renovascular Hypertension Diseases 0.000 abstract 1
- 201000004239 Secondary hypertension Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010042957 Systolic hypertension Diseases 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 229960004530 benazepril Drugs 0.000 abstract 1
- 229960003619 benazepril hydrochloride Drugs 0.000 abstract 1
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 abstract 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 238000009109 curative therapy Methods 0.000 abstract 1
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960002680 enalaprilat Drugs 0.000 abstract 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 229960005170 moexipril Drugs 0.000 abstract 1
- 238000002638 palliative care Methods 0.000 abstract 1
- 229960002582 perindopril Drugs 0.000 abstract 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 abstract 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 229960001455 quinapril Drugs 0.000 abstract 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 abstract 1
- 229960003042 quinapril hydrochloride Drugs 0.000 abstract 1
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 abstract 1
- 229960000835 tadalafil Drugs 0.000 abstract 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
- 229960002381 vardenafil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0211919A GB0211919D0 (en) | 2002-05-23 | 2002-05-23 | Novel combination |
| GB0229784A GB0229784D0 (en) | 2002-12-20 | 2002-12-20 | Novel combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040090A1 true AR040090A1 (es) | 2005-03-16 |
Family
ID=29585817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101762A AR040090A1 (es) | 2002-05-23 | 2003-05-21 | Nueva combinacion |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1506015A2 (https=) |
| JP (1) | JP2005529927A (https=) |
| KR (1) | KR20050004195A (https=) |
| CN (1) | CN1655820A (https=) |
| AR (1) | AR040090A1 (https=) |
| AU (1) | AU2003223071A1 (https=) |
| BR (1) | BR0311191A (https=) |
| CA (1) | CA2485984A1 (https=) |
| IL (1) | IL164975A0 (https=) |
| MX (1) | MXPA04010951A (https=) |
| NO (1) | NO20045517L (https=) |
| PA (1) | PA8574201A1 (https=) |
| PE (1) | PE20040514A1 (https=) |
| PL (1) | PL374198A1 (https=) |
| RU (1) | RU2004133973A (https=) |
| TW (1) | TW200407153A (https=) |
| UY (1) | UY27816A1 (https=) |
| WO (1) | WO2003099194A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| GB0318094D0 (en) * | 2003-08-01 | 2003-09-03 | Pfizer Ltd | Novel combination |
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| FR2902009B1 (fr) * | 2006-06-13 | 2012-12-07 | Bioprojet Soc Civ | Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire |
| JP2010501577A (ja) | 2006-08-24 | 2010-01-21 | サーフェイス ロジックス，インコーポレイティド | 薬物動態が改善された化合物 |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| EP3167876B1 (en) | 2012-03-15 | 2021-09-08 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| EP3021832B9 (en) | 2013-07-19 | 2023-03-15 | Boehringer Ingelheim Vetmedica GmbH | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| CA2930033C (en) | 2013-12-04 | 2022-12-13 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4316906A (en) * | 1978-08-11 | 1982-02-23 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of substituted prolines |
| GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| US6362178B1 (en) * | 1997-11-12 | 2002-03-26 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| AP2002002455A0 (en) * | 1999-10-11 | 2002-06-30 | Pfizer | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors. |
-
2003
- 2003-05-09 CN CNA038118262A patent/CN1655820A/zh active Pending
- 2003-05-09 BR BR0311191-1A patent/BR0311191A/pt not_active IP Right Cessation
- 2003-05-09 KR KR10-2004-7018868A patent/KR20050004195A/ko not_active Abandoned
- 2003-05-09 JP JP2004506721A patent/JP2005529927A/ja not_active Abandoned
- 2003-05-09 EP EP03719042A patent/EP1506015A2/en not_active Withdrawn
- 2003-05-09 MX MXPA04010951A patent/MXPA04010951A/es unknown
- 2003-05-09 AU AU2003223071A patent/AU2003223071A1/en not_active Abandoned
- 2003-05-09 PL PL03374198A patent/PL374198A1/xx not_active Application Discontinuation
- 2003-05-09 WO PCT/IB2003/001889 patent/WO2003099194A2/en not_active Ceased
- 2003-05-09 CA CA002485984A patent/CA2485984A1/en not_active Abandoned
- 2003-05-09 RU RU2004133973/15A patent/RU2004133973A/ru not_active Application Discontinuation
- 2003-05-12 TW TW092112826A patent/TW200407153A/zh unknown
- 2003-05-19 PE PE2003000482A patent/PE20040514A1/es not_active Application Discontinuation
- 2003-05-21 AR ARP030101762A patent/AR040090A1/es unknown
- 2003-05-21 UY UY27816A patent/UY27816A1/es not_active Application Discontinuation
- 2003-05-22 PA PA20038574201A patent/PA8574201A1/es unknown
-
2004
- 2004-11-01 IL IL16497504A patent/IL164975A0/xx unknown
- 2004-12-17 NO NO20045517A patent/NO20045517L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL374198A1 (en) | 2005-10-03 |
| CA2485984A1 (en) | 2003-12-04 |
| MXPA04010951A (es) | 2005-06-08 |
| JP2005529927A (ja) | 2005-10-06 |
| AU2003223071A1 (en) | 2003-12-12 |
| NO20045517L (no) | 2004-12-17 |
| PE20040514A1 (es) | 2004-08-24 |
| IL164975A0 (en) | 2005-12-18 |
| KR20050004195A (ko) | 2005-01-12 |
| UY27816A1 (es) | 2003-12-31 |
| BR0311191A (pt) | 2005-03-01 |
| PA8574201A1 (es) | 2003-12-19 |
| WO2003099194A2 (en) | 2003-12-04 |
| CN1655820A (zh) | 2005-08-17 |
| WO2003099194A3 (en) | 2004-06-03 |
| TW200407153A (en) | 2004-05-16 |
| RU2004133973A (ru) | 2005-09-10 |
| EP1506015A2 (en) | 2005-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040090A1 (es) | Nueva combinacion | |
| RU2008131792A (ru) | Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора pdev | |
| ME02207B (me) | UPOTREBA sGC STIMULATORA, sGC AKTIVATORA, POJEDINAČNO I U KOMBINACIJI SA PDE5 INHIBITORIMA ZA TRETMAN SISTEMSKE SKLEROZE (SSc) | |
| US5366973A (en) | Mercaptoacetylamido pyridazo [1,2]pyridazine, pyrazolo[1,2]pyridazine pyrazolo[1,2]pyridazine, pyridazol[1,2-a][1,2]diazepine and pyrazolol[1,2-a][1,2]diazepine | |
| PE20010815A1 (es) | Uso de inhibidores de 3`,5'-guanosinmonofosfato ciclico fosfodiesterasa para el tratamiento de la hipertension pulmonar | |
| ES2606717T3 (es) | Inhibidores del virus de la hepatitis C | |
| JP6591530B2 (ja) | 有機化合物 | |
| NO20043851L (no) | Derivater av 4-(imidazol-5-yl)-2-(4-sulfoanilino) pyrimidin med CDK inhibitorisk aktivitet | |
| BG103655A (bg) | Дизаместени бициклични хетероциклени съединения, тяхното получаване и приложението им като лекарствени средства | |
| EP0802916A1 (en) | Low molecular weight bicyclic thrombin inhibitors | |
| NO20053955L (no) | Pyrazolo [1,5-A] pyrimidinderivater | |
| NZ618691A (en) | Fused benzoxazepinones as ion channel modulators | |
| EP1799218A1 (en) | Hcv inhibiting bi-cyclic pyrimidines | |
| JP2016538316A5 (https=) | ||
| AR040337A1 (es) | Uso de una combinacion de un inhibidor de fosfodiesterasa tipo 5 (pde5) especifica de monofosfato de guanosina ciclico (gmpc) y un antagonista del receptor de angiotensina ii para preparar un medicamento | |
| RU2013151293A (ru) | Производные n-[(1н-пиразол -1-ил) арил]-1н-индола или 1н-индазол-3-карбоксамида, их получение и их применение в качестве антагонистов p2y12 | |
| JP2006528229A5 (https=) | ||
| JP2005529927A5 (https=) | ||
| AR044648A1 (es) | Combinaciones terapeuticas | |
| CA2072233A1 (en) | Triazolopyrimidine derivatives which are angiotensin ii receptor antagonists; processes for preparing them and pharmaceutical compositions containing them | |
| AU2005274546B2 (en) | Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders | |
| US5236933A (en) | Use of a combination of angiotensin-converting enzyme inhibitor and calcium antagonist for the treatment of proteinuria | |
| WO2007050510A2 (en) | Hiv integrase inhibitors | |
| AU3889301A (en) | Blood pressure stabilization during hemodialysis | |
| CA2527375C (en) | Beta-strand mimetics and methods relating thereto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |